Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 4, 2006, Pages 289-296

  Zdzisińska, Barbara ^a   Walter Croneck, Adam ^b   Dmoszyńska, Anna ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Bone marrow adherent cells; Cytokines; Matrix metalloproteinases; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 11; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; MULTIPLE MYELOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; ZYMOGRAPHY;

ADULT; BONE MARROW CELLS; CELL ADHESION; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; MULTIPLE MYELOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747177086     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0033-z     Document Type: Article

References (33)

1. Azuma Y., Kaji K., Katogi R., Takeshita S. and Kudo A. (2000): Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem., 275, 4858-4864.
2. Barille S., Akhoundi C., Collette M., Mellerin M. P., Rapp M. J., Harousseau J. L., Bataille R. and Amiot M. (1997): Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood, 90, 1649-1655.
3. Barille S., Bataille R., Rapp M. J., Harousseau J. L. and Amiot M. (1999): Production of matalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immunol., 163, 5723-5728.
4. Barton B. E. and Murphy T. F. (2000): Constitutive expression of IL-6-like cytokines in normal bone marrow: implications for pathophysiology of myeloma. Cytokine, 12, 1537-1545.
5. Bord S., Horner A., Hembry R. M. and Compston J. E. (1998): Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development. Bone, 23, 7-12.
6. Borset M., Waage A., Brekke O. L. and Helseth E. (1994): TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur. J. Haematol., 53, 31-37.
7. Cheleuitte D., Mizuno S. and Glowacki J. (1998): In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J. Clin. Endocrinol. Metab., 83, 2043-2051.
8. Derenne S., Amiot M., Barille S., Collette M., Robillard N., Berthaud P., Harousseau J. L. and Bataille R. (1999): Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res., 14, 2048-2057.
9. Drach J., Kaufmann H., Urbauer E., Schreiber S., Ackermann J. and Huber H. (2000): The biology of multiple myeloma. J. Cancer Res. Clin. Oncol., 126, 441-447.
10. Durie B. G. and Salmon S. E. (1975): A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36,842-854.
11. Dührsen U. and Hossfeld D. K. (1996): Stromal abnormalities in neoplastic bone marrow diseases. Ann. Hematol., 73, 53-70.
12. Forget M. A., Desrosiers R. R. and Beliveau R. (1999): Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can. J. Physiol. Pharmacol., 77, 465-480.
13. Gregoretti M. G., Gottardi D., Ghia P., Bergui L., Merico F., Marchisio P. C. and Caligaris-Cappio F. (1994): Characterization of bone marrow stromal cells from multiple myeloma. Leukemia Res., 18, 675-682.
14. Hallek M., Bergsagel P. L. and Anderson K. C. (1998): Multiple myeloma: increasing evidence for a multiple transformation process. Blood, 91, 3-21.
15. Heussen C. and Dowdle E. B. (1980): Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem., 102, 196-202.
16. Hideshima T., Chauhan D., Schlossman R., Richardson P. and Anderson K. C. (2001): The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 20, 4519-4527.
17. Jelinek D. F. (1999): Mechanisms of myeloma cell growth control. Hematol. Oncol. Clin. North Am., 13, 1145-1157.
18. Jourdan M., Zhang X. G. and Portier M. (1991): IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J. Immunol., 147, 4402-4407.
19. Kasper C., Lubking A., Beelen D. W. and Duhrsen U. (2004): Interferon alpha (IFN) treatment of bone marrow stroma inhibits haematopoiesis. Leuk. Res., 28, 1217-1220.
20. Kelly T., Borset M., Abe E., Gaddy-Kurten D. and Sanderson R. D. (2000): Matrix metalloproteinases in multiple myeloma. Leuk. Lymphoma, 37, 273-281.
21. Klein B. (1995): Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Sem. Hematol., 32, 4-19.
22. Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H., Kamoi K. and Suda T. (1998): Regulation of matrix metalloproteinases (MMP-2,-3,-9 and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology, 139, 1338-1345.
23. Lokhorst H. M., Lamme T., De Smet M., Klein S., De Weger R. A., Van Oers R. and Bloem A. C. (1994): Primary tumor cells of myeloma patients induce IL-6 secretion in long-term bone marrow cultures. Blood, 84, 2269-2277.
24. Lorenzo J. A., Pilbeam C. C., Kalinowski J. F. and Hibbs M. S. (1992): Production of both 92 and 72-kDa gelatinases by bone cells. Matrix, 12, 282-290.
25. Marquez-Curtis L. A, Dobrowski A., Montano J., Turner A. R., Ratajczak J., Ratajczak M. Z. and Janowska-Wieczorek A. (2001): Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br. J. Haematol., 115, 595-604.
26. Meikle M. C., Bord S., Hembry R. M., Compston J., Croucher P. I. and Reynolds J. J. (1992): Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J. Cell Sci., 103 (Pt 4), 1093-1099.
27. Sensebe L., Deschaseaux M., Li J., Herve P. and Charbord P. (1997): The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment. Stem Cells, 15, 133-143.
28. Stamenkovic I. (2000): Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol., 10, 415-433.
29. Takeuchi Y., Watanabe S., Ishii G., Takeda S., Nakayama K., Fukumoto S., Kaneta Y., Inoue D., Matsumoto T., Harigaya K. and Fujita T. (2002): Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biol. Chem., 277, 49011-49018.
30. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., Albini A., Bussolino F. and Dammacco F. (1999): Bone marrow neovascularization, plasma cell angiostatic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073.
31. Van Vlasselaer P., Borremans B., Van Den Heuvel R., Van Gorp U. and de Waal Malefyt R. (1993): Interleukin-10 inhibits the osteogenic activity of mouse bone marrow. Blood, 82, 2361-2370.
32. Wallace S. R., Oken M. M., Lunetta K. L., Panoskaltsis-Mortari A. and Masellis A. M. (2001): Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer, 91, 1219-1230.
33. Wei S., Kitaura H., Zhou P., Ross F. P. and Teitelbaum S. L. (2005): IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest., 115, 282-290.